Literature DB >> 9864076

Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review.

N Bonhomme1, E Esposito.   

Abstract

Several hypotheses regarding the physiopathology of major depression exist. Attention has been focused on cerebral monoaminergic systems, the dysfunction of which is thought to underlie various aspects of depressive symptomatology. There is extensive literature describing the involvement of serotonergic and dopaminergic systems in the mechanism of action of antidepressant drugs. However, a unitary analysis of the data in terms of interaction between different monoaminergic systems is still lacking. In this article, studies reporting the biochemical, behavioral, and clinical effects of tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), selective blockers of presynaptic dopamine (DA) receptors, and antagonists of serotonin-2 (5-hydroxytryptamine-2 [5-HT2]) receptors were reviewed. Analysis of the current literature indicates that long-term treatment with antidepressants causes adaptive changes of the serotonergic and dopaminergic systems. In particular, long-term administration of TCAs enhances the responsiveness of postsynaptic serotonin receptors to iontophoretically applied serotonin and potentiates the behavioral responses to both direct and indirect dopaminergic agonists. Repeated administration of SSRIs and MAOIs increases serotonergic transmission by desensitizing the inhibitory 5-HT1A somatodendritic and terminal 5-HT1B/1D autoreceptors. Selective blockers of DA autoreceptors exert their antidepressant effect by enhancing DA release. A similar mechanism of action could be hypothesized for 5-HT2 receptor antagonists. There is general agreement that the clinical effect of antidepressant drugs, which becomes evident only after long-term treatment, is caused by their ability to induce adaptive changes of the monoaminergic systems. Increases in both serotonergic and dopaminergic function have been consistently found after long-term treatment with various classes of antidepressant drugs. Recent studies have focused on the functional interaction between the serotonergic and dopaminergic systems to explain the mechanism of the antidepressant action of SSRIs and 5-HT2 antagonists.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9864076     DOI: 10.1097/00004714-199812000-00005

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  23 in total

Review 1.  Opponency revisited: competition and cooperation between dopamine and serotonin.

Authors:  Y-Lan Boureau; Peter Dayan
Journal:  Neuropsychopharmacology       Date:  2010-09-29       Impact factor: 7.853

Review 2.  Current status of functional imaging in eating disorders.

Authors:  Guido K W Frank; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2012-04-25       Impact factor: 4.861

3.  Mechanism-based inhibition of the melatonin rhythm enzyme: pharmacologic exploitation of active site functional plasticity.

Authors:  E M Khalil; J De Angelis; M Ishii; P A Cole
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 4.  Neurobiology of anorexia and bulimia nervosa.

Authors:  Walter Kaye
Journal:  Physiol Behav       Date:  2007-11-29

5.  Effect of the antidepressant nefazodone on the density of cells expressing mu-opioid receptors in discrete brain areas processing sensory and affective dimensions of pain.

Authors:  Antonio Ortega-Alvaro; Ignacio Acebes; Gonzalo Saracíbar; Enrique Echevarría; Luis Casis; Juan Antonio Micó
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

6.  The reward system and maternal behavior in an animal model of depression: a microdialysis study.

Authors:  Yael Lavi-Avnon; Aron Weller; John P M Finberg; Iris Gispan-Herman; Noa Kinor; Yaakov Stern; Mariana Schroeder; Vered Gelber; S Yoav Bergman; David H Overstreet; Gal Yadid
Journal:  Psychopharmacology (Berl)       Date:  2007-10-11       Impact factor: 4.530

7.  Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness.

Authors:  Ursula F Bailer; Julie C Price; Carolyn C Meltzer; Chester A Mathis; Guido K Frank; Lisa Weissfeld; Claire W McConaha; Shannan E Henry; Sarah Brooks-Achenbach; Nicole C Barbarich; Walter H Kaye
Journal:  Neuropsychopharmacology       Date:  2004-06       Impact factor: 7.853

8.  In vivo oxymetric analysis of mild hypercapnia upon cerebral oxygen, temperature and blood flow: markers of mood as proposed by concomitant bupropion challenge and electrochemical analysis?

Authors:  Francesco Crespi
Journal:  Exp Brain Res       Date:  2013-03-17       Impact factor: 1.972

9.  A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.

Authors:  Stephen M. Stahl; James F. Pradko; Barbara R. Haight; Jack G. Modell; Carol B. Rockett; Susan Learned-Coughlin
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

10.  Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.

Authors:  Hideki Taoka; Takashi Hamamura; Shiro Endo; Shinji Miyata; Kishio Toma; Takeshi Ishihara; Shigetoshi Kuroda
Journal:  Psychopharmacology (Berl)       Date:  2008-09-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.